; on behalf of the SMART study group Abstract Background: The ratio of estimated glomerular filtration rate (eGFR) to kidney size reflects the kidney's capacity for filtration per kidney volume or kidney length. High ratios of eGFR to kidney size, which might indicate glomerular hyperfiltration, could be related to kidney function decline, cardiovascular disease and mortality. Methods: In 6926 patients with clinically manifest vascular disease, we evaluated the relationship between eGFR/kidney size and the risk of cardiovascular events and all-cause mortality using Cox regression. Quartiles were made for eGFR/ kidney size, using the second quartile as the reference category. In 1516 patients with second measurements of eGFR, linear regression was used to evaluate the relationship between eGFR/kidney size and annual kidney function decline. Results: The relationship between eGFR/kidney size and all-cause mortality followed a reversed J-shaped curve with increased risk for the lowest (hazard ratio (HR) 1.17; 95% confidence interval (CI) 1.01-1.36) and highest quartile (HR 1.04; 95% CI 0.87-1.25) of eGFR/volume, and for the lowest (HR 1.37;95%CI 1.19-1.59) and highest quartile (HR 1.28; 95% CI 1.06-1.54) of eGFR/length. The risk for cardiovascular events was increased for the lowest quartile of eGFR/length (HR 1.55; 95% CI 1.33-1.82). An increase in eGFR/volume and eGFR/length, was related to a greater kidney function decline, b À0.34 (95% CI À0.42 to À0.26) and b À0.55 (95% CI À0.63 to À0.48) ml/min/1.73 m 2 per year respectively. Conclusions: High eGFR/volume and eGFR/length, which might indicate glomerular hyperfiltration, are related to kidney function decline. High eGFR/length confers an increased risk for all-cause mortality in patients with clinically manifest vascular disease.
Introduction
It has been convincingly shown that the risk for cardiovascular disease and mortality increases with decreasing glomerular filtration rates (GFRs).
1,2 Experimental evidence suggests that glomerular hyperfiltration is one of the key mechanisms in the process of chronic kidney disease progression. 3 Recently, renal hyperfiltration was introduced as a novel marker of all-cause mortality in an apparently healthy population. 4 Thus, both experimental and previously mentioned limited clinical evidence suggests that glomerular hyperfiltration may play a role in deterioration of kidney function and increased risk for mortality.
The presence of glomerular hyperfiltration has mainly been described in patients with diabetes but is also related to hypertension and obesity, all of which are prevalent comorbidities in patients with clinically manifest vascular disease. 5, 6 The effect of glomerular hyperfiltration in patients with clinically manifest vascular disease is unknown but could be related to a deterioration of kidney function, increased risk of subsequent vascular events and mortality.
High estimated glomerular filtration rate (eGFR) is sometimes used to define glomerular hyperfiltration but this can be blurred by the physiological decline with age. 7 In patients at high cardiovascular risk both eGFR and kidney size decline with age. 8 The ratio of eGFR to kidney size reflects the capacity to filtrate per kidney volume or length and allows for interpretation of eGFR per unit kidney tissue. This may be a surrogate for single nephron GFR with high values reflecting glomerular hyperfiltration.
The aims of the present study are twofold: (a) to assess the relationship between eGFR/kidney volume and eGFR/kidney length, as a proxy measure for glomerular hyperfiltration, and occurrence of subsequent cardiovascular events and all-cause mortality, and (b) to assess the relationship between eGFR/kidney volume and eGFR/kidney length and annual kidney function decline.
Subjects and methods Subjects
The study population consisted of patients enrolled in the Second Manifestations of ARTerial disease (SMART) study, an ongoing prospective single-centre cohort study at the University Medical Center Utrecht, the Netherlands. The aim of the SMART study is to determine the prevalence of concomitant asymptomatic arterial disease and risk factors for atherosclerotic disease in patients presenting with a manifestation of arterial disease or risk factor, and to study the incidence of future cardiovascular events and its predictors in these high-risk patients. The inclusion of patients started in September 1996. Inclusion criteria were age of 18-80 years and a recent or pre-existing diagnosis of clinically manifest arterial disease (cerebrovascular disease, coronary heart disease, peripheral arterial disease or abdominal aortic aneurysm), or with increased risk for atherosclerotic vascular disease (hypertension, diabetes, hyperlipidaemia). Exclusion criteria were pregnancy, terminal malignant disease, not being independent in daily activities or insufficient fluency in the Dutch language. Eligible patients received written and oral information about the goals and methodology of the cohort study from qualified research nurses. Patients were approached either via the outpatient clinic or during the weeks after hospital discharge. All patients were clinically stable during recruitment. From January 2006 onwards patients who had been included for at least three years were invited for second measurements similar to those taken at baseline. All study patients gave their written informed consent. The SMART study was approved by the ethics committee at the University Medical Center Utrecht. Detailed information on the rationale and design has been described elsewhere. 9 For the present study we used data from all patients with clinically manifest vascular disease (n ¼ 7223). Patients with missing data on ultrasonography of the kidneys (n ¼ 151), end stage kidney disease defined as eGFR < 15 (n ¼ 50), abnormal kidney size due to underlying disease including polycystic kidney disease (n ¼ 4), small kidneys defined as a kidney length <7 cm or kidney volume <50 cm 3 (n ¼ 51) or nephrectomy in medical history (n ¼ 41) were excluded. In total, 6926 patients were eligible for analyses on cardiovascular events and all-cause mortality. Second measurements were available in 1522 of these patients. Another six patients were excluded due to missing data on second measurements of creatinine, leaving 1516 patients for analysis on kidney function decline.
Measurements
Patients were asked to fill in a questionnaire regarding their medical history. Physical examination was performed including office blood pressure measurement. Fasting blood and urine samples were taken. Ultrasonography was performed according to protocol by well-trained vascular technologists to register kidney size using an ATL HDI 3000 (Advanced Technology Laboratories, Bothell) equipped with a 4-2MHz curved array transducer. Kidney length was measured as the maximum pole to pole length in the oblique sagittal plane. Maximum anteroposterior and left-to-right kidney dimensions were measured in the transverse plane. Kidney volume was calculated using the ellipsoid formula: 10 volume ¼ length Â depth Â width Â =6
Definitions
The ratio of eGFR to kidney size was defined as eGFR per mean kidney volume as eGFR/volume (eGFR/cm 3 ) and eGFR per mean kidney length as eGFR/length (eGFR/cm). EGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 creatinine equation. 11 For patients with van der Sande et al.
second measurements, kidney function decline was defined as the absolute annual change in eGFR calculated as: (follow-up eGFR -baseline eGFR/follow-up in years. Albuminuria was defined by a albumin/creatinine ratio>2.5 mg/mmol for males and >3.5 mg/ mmol for females. Diabetes was defined as fasting serum glucose !7.0 mmol/l, self-reported diabetes and/or use of insulin or oral hypoglycaemic drugs.
Follow-up and outcome evaluation
Patients were biannually asked to fill in a questionnaire on hospitalisations and outpatient clinic visits for cardiovascular events. All available data on reported events was collected and independently reviewed by three members of the SMART endpoint committee composed of physicians from different medical departments. The cardiovascular events of interest for the present study included myocardial infarction, stroke, cardiovascular mortality, the composite of cardiovascular events and all-cause mortality (Supplementary Material, Supplemental Table 1 ). In total 370 patients (5.3%) were lost to follow-up.
Data analyses
The baseline characteristics are presented as sex-pooled quartiles (Q) of eGFR/volume and eGFR/length (Q4 reflecting highest values of the ratio of eGFR per kidney size) to provide an equal distribution of males and females in each quartile. The relationship between eGFR/volume, eGFR/length and cardiovascular events and all-cause mortality was evaluated by Cox proportional hazard models including linear and quadratic terms for eGFR/volume and eGFR/length. The results were adjusted for potential confounders measured at baseline including age, sex, diabetes, albuminuria, systolic blood pressure, body mass index (BMI), smoking and use of renin-angiotensin system (RAS) inhibitors.
Results are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). Adjusted HRs were graphically presented using restricted cubic splines between the 5 th and 95 th percentile of eGFR/kidney size (i.e. between 0.3-0.7 for eGFR/cm 3 and between 4-9 for eGFR/cm). Four knots were taken while using the lowest point as a reference, this was at 0.43 for eGFR/volume and 7.0 for eGFR/length. The p-values of overall and nonlinear effect of eGFR/volume and eGFR/length on the outcomes of interest were based on 2 statistic. Next, eGFR/volume and eGFR/length were divided into quartiles, using the second quartile as the reference, to quantify the observed relationship with cardiovascular events and all-cause mortality.
Sensitivity analyses were performed by excluding events that took place in the first year of follow-up to address the issue where high eGFR/kidney size may be the result of a falsely high eGFR due to low muscle mass in severely ill patients. Furthermore, kidney volume and kidney length were corrected for body height by dividing kidney size by body height in m, since kidney size is related to anthropometric characteristics. 12 Lastly, subgroup analyses were performed in patients with an eGFR of <75 and !75 ml/min/1.73 m 2 . Proportional hazard assumptions were evaluated using Schoenfeld residuals. Visual inspection showed no non-proportionality.
Linear regression analysis was performed to examine the relationship between eGFR/volume, eGFR/length and kidney function decline. Two models were made with confounders measured at baseline, the first model included age and sex, the second model included age, sex, diabetes, albuminuria, systolic blood pressure, BMI, smoking and use of RAS inhibitors. To evaluate if eGFR/volume and eGFR/length were related to kidney function decline in patients with a normal or mildly decreased kidney function, the analyses were repeated according to eGFR categories as defined for chronic kidney disease staging by Kidney Disease Improving Global Outcomes (KDIGO). 13 Patients were classified by eGFR above 89, between 60-89 and below 60 ml/min/1.73 m 2 . We evaluated model assumptions including homogeneity of residuals and multicollinearity. There was no violation observed.
Missing data for albuminuria (3.7%), systolic blood pressure (0.2%), smoking (0.6%) and BMI (0.2%) were imputed using bootstrapping and predictive mean matching (aregImpute-algorithm in R, Hmiscpackage).
14 Probability values less than 0.05 were considered significant. All analyses were performed with R statistical software version 3.0.3 (http://R-project.org).
Results

Baseline characteristics
In total, 5112 men and 1814 women were included. The median follow-up was 7.0 years (interquartile range 3.8-10.4) with a total follow-up time of 50,380 person years. The ratio of eGFR/volume ranged between 0.08-1.19 in men and 0.11-1.46 in women (Table 1) . Patients with high eGFR/volume were on average younger, had lower BMI, had higher eGFR, were less likely to have albuminuria or a history of diabetes and were less likely to use RAS inhibitors than those with low eGFR/volume. Patients with high eGFR/volume had on average the lowest kidney volume.
The ratio of eGFR/length ranged from 1.3-12.5 in men and 1.5-13.5 in women (Supplementary Material, Supplemental Table 2 ). Patients with high eGFR/length were also younger, less likely to have albuminuria or a history of diabetes and were less likely to use RAS inhibitors. The 1516 patients with second measurements were more likely to be male and less likely to have diabetes compared to the 5410 patients without second measurements (Supplementary Material, Supplemental Table 3 ).
Relationship between eGFR/volume, eGFR/length and kidney function
Compared to eGFR/length, eGFR/volume showed higher dispersion in relation to eGFR (Figure 1 ). This indicates that there is considerable variation in kidney volume in patients with similar eGFR, while kidney length varies less in patients with similar eGFR.
Relationship between the ratio of eGFR to kidney size and cardiovascular events and all-cause mortality A total of 1117 subsequent cardiovascular events occurred (composite of myocardial infarction, stroke and cardiovascular death) and 1235 patients died of any cause. The relationship between eGFR/volume and the occurrence of myocardial infarction, cardiovascular mortality, cardiovascular events and allcause mortality followed a reversed J-shaped curve (Supplementary Material, Supplemental Figure 1 ). Patients in the lowest quartile of eGFR/volume were at increased risk of all-cause mortality (HR 1.17; 95% CI 1.01-1.36) compared to patients in the second quartile of eGFR/volume (Table 2) . There was a similar relationship between eGFR/ length and the occurrence of myocardial infarction, stroke, cardiovascular mortality, cardiovascular events and all-cause mortality (Supplementary Material, Supplemental Figure 2 ). There was an increased risk of all-cause mortality (HR 1.28; 95% CI 1.06-1.54) for patients in the highest quartile of eGFR/length compared to the second quartile of eGFR/length. Patients in the lowest quartile of eGFR/length were at increased risk for myocardial infarction (HR 1.40; 95% CI 1.13-1.73), stroke (HR 1.53; 95% CI 1.13-2.06), cardiovascular mortality (HR 1.50; 95% CI 1.23-1.83), cardiovascular events (HR 1.55; 95% CI 1.33-1.82) and all-cause mortality (HR 1.37; 95% CI 1.19-1.59) compared to patients in the second quartile of eGFR/ length.
Sensitivity analyses for the relationship between the ratio of eGFR to kidney size and cardiovascular events and all-cause mortality
To determine whether falsely high eGFRs due to low muscle mass in critically ill patients could affect the relationship between the ratios of eGFR to kidney size and cardiovascular events and all-cause mortality we performed the same analyses after excluding events occurring in the first year which revealed similar results (Supplementary Material, Supplemental Table 4 ). Furthermore, correcting kidney length and volume for body height did not change the results (Supplementary Material, Supplemental Table 5 ).
Subgroup analyses based on baseline eGFR
In the subgroup of patients with low eGFR (<75 ml/ min/1.73 m 2 ), those in the highest quartile of eGFR/ length were not at increased risk for all-cause mortality (HR 0.99; 95% CI 0.79-1.25) (Supplementary Material, Supplemental Table 6 ). In the subgroup of patients with high eGFR(!75 ml/min/1.73 m 2 ), those in the highest quartile of eGFR/length remained at increased risk of all-cause mortality (HR 1.50; 95% CI 1.14-1.97) (Supplementary Material, Supplemental Table 7) .
Relationship between the ratio of eGFR to kidney size and annual kidney function decline Second creatinine measurements were taken after a median of 9.3 years (interquartile range 4.4-10.9). Mean annual change in kidney function was À0.81 ml/min/1.73 m 2 , indicating a yearly decline. Overall, an increase of 0.1 in eGFR/volume was related to a greater absolute kidney function decline of À0.34 (95% CI À0.42 to À0.26) ml/min/1.73 m 2 per year (Table 3) . For eGFR/length, an increase of one in eGFR/length was related to a greater absolute kidney function decline of À0.55 (95% CI À0.63 to À0.48) ml/ min/1.73 m 2 per year. This indicates that the higher the ratio of eGFR/volume and eGFR/length, the stronger the decline in eGFR.
In the subgroup of patients with an eGFR between 60-89 ml/min/1.73 m 2 , an increase of 0.1 in eGFR/ volume was related to a sharper decline in eGFR of À2.06 (95% CI À3.10 to À1.02) ml/min/1.73 m 2 per year. An increase of one in eGFR/length was related to a sharper decline of À58 (95% CI À0.82 to À0.34) in patients with an eGFR above 90 ml/min/1.73 m 2 and to a sharper decline of À0.49 (95% CI À0.62 to À0.35) in patients with an eGFR between 60-89 ml/ min/1.73 m 2 .
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Discussion
In patients with clinically manifest vascular disease, high eGFR/length was related to higher risk of allcause mortality. Secondly, an increase in eGFR/ volume and eGFR/length was related to greater kidney function decline.
Our study results show that in patients with clinically manifest cardiovascular disease, a high eGFR/ kidney size is related to clinically relevant outcomes, such as mortality and kidney function decline. High eGFR/kidney size ratios may indicate hyperfiltration. However, further evaluation of the relationship between hyperfiltration and high eGFR/kidney size ratios is needed to support this hypothesis. Although assessed differently, the relationship between renal hyperfiltration and increased risk of all-cause mortality was observed in a recent study in an apparently healthy Korean population. 4 Contrary to eGFR/length, high eGFR/volume was not related to increased risk of all-cause mortality when comparing quartiles of eGFR/volume. The discrepancy between eGFR/volume and eGFR/length may result from the fact that kidney volume was estimated while kidney length was directly measured. Yet, kidney volume is expected to reflect the functional capacity of the kidneys more accurately than kidney length because kidney volume as measured by ultrasound correlates well to true kidney volume and kidney mass, which in turn is correlated to glomerular number. [15] [16] [17] Importantly, the present data seem to support the idea that glomerular hyperfiltration is related to chronic kidney disease progression in humans. For patients with normal to mildly decreased kidney function, there was a wide range in the ratios of eGFR/volume and eGFR/length. This means that the size of the kidney substantially varies for a given level of eGFR in that range. This was to a lesser extent observed in lower levels of eGFR. Overall, higher eGFR/volume and eGFR/length were related to a stronger kidney function decline. This was particularly apparent in normal to mildly decreased kidney function.
It is unclear if there is a direct causal relationship between glomerular hyperfiltration and increased risk of mortality. Several mechanisms may be involved in the pathophysiology of glomerular hyperfiltration including increased activities of the RAS and the sympathetic nervous system. 18, 19 In patients with cardiovascular disease, sympathetic overactivity is also related to increased risk of mortality. 20 It is highly possible, that glomerular hyperfiltration should be interpreted as a marker for the presence of mechanisms relevant in the pathogenesis of both cardiovascular disease and chronic kidney disease progression. In patients with high eGFR/volume or eGFR/length, conditions known to be associated with glomerular hyperfiltration such as diabetes, high blood pressure and obesity tended to be less prevalent. 5, 6 Subgroup analyses demonstrated that high eGFR/length was related increased risk of all-cause mortality and to kidney function decline only in patients who are considered to have normal kidney function. We could not support this observation by performing interaction analyses due to multicollinearity between eGFR/kidney size and eGFR. However, the change in effect estimates makes presence of interaction by eGFR likely. The results of the present study can serve as the rationale to use these ratios to identify patients at high risk of mortality and kidney function decline who would not be classified as such based on eGFR levels. These patients with normal kidney function might benefit from renoprotective medication such as RAS inhibitors or an increase in dosage, since use of RAS inhibition was lowest in patients with high eGFR/volume and eGFR/length.
The major strength of this study is the large number of patients and the prospective cohort study design with sufficient follow-up time and relevant clinical outcomes. Ultrasonography was performed according to a highly standardised protocol by welltrained technicians.
Some study limitations need to be considered. A previous study on accuracy and repeatability of ultrasonography conducted at the University Medical Center Utrecht reported that magnetic resonance imaging is more reliable in measuring kidney size. 21 The intraand interobserver mean difference of the measurements were À0.01 cm (95% CI À1.36-1.33) and À0.07 cm (95% CI À1.27-1.13) for the kidney length measurements and À4.8 ml (95% CI À61.0-51.5) and À18.7 ml (95% CI À81.9-44.6) for the kidney volume measurements. However ultrasonography is mostly used in clinical practice during the initial assessment of kidney function disorders and therefore enhances applicability of our study results. During the study there was limited loss to follow-up lowering the risk of bias. However survival bias could have occurred in the analyses where second measurements were used. This could have led to selection of healthier patients and a underestimation of annual kidney function decline in our study population. Furthermore, the assessment of kidney function and kidney function decline was based on estimated GFR measurements using the CKDEPI equation. Although most used in clinical practice, CKDEPI can overestimate in patients with low muscle mass. Finally, kidney function decline was assessed on the basis of two measurements although it is preferable to take more than two measurements over time to establish a decline. 13 In conclusion, high eGFR/volume and eGFR/ length, which might indicate the presence of glomerular hyperfiltration, are related to the rate of kidney function decline in patients with clinically manifest vascular disease. High eGFR/length confers an increased risk for all-cause mortality. The combination of kidney function and kidney size may be useful for identification of patients at risk of mortality and kidney function deterioration, who would otherwise not be classified as such based on eGFR levels.
